ASTRIA CONNECTION

Special edition
December 2022

Exciting Results from Our Phase 1a Trial: What's Next for STAR-0215

We are very excited to share positive preliminary data from our Phase 1a trial in healthy volunteers! These data support STAR-0215's target profile of being a long-acting preventative therapy for HAE dosed subcutaneously (under the skin) once every three months or less frequently. We are driven to help people with HAE and their families normalize their lives by developing a treatment that allows them to focus their time and energy on what matters most to them. In early 2023, we plan to advance to the next stage in the drug development process by starting a Phase 1b/2 clinical trial evaluating STAR-0215 in people living with HAE. Read on to learn more about the preliminary results and the upcoming ALPHA-STAR global trial!

Phase 1a Trial Overview and Results

25 **healthy adult participants have received** **a single dose of STAR-0215** *(either 100 mg, 300 mg, or 600 mg)* **or** **placebo** *(looks like STAR-0215 but does not contain STAR-0215)*

Phase 1a Goal

To collect information on STAR-0215's safety and tolerability, its amounts circulating in the body (pharmacokinetics), and its effects on the body (pharmacodynamics).

PRELIMINARY DATA FROM THIS STUDY[1] SHOW

STAR-0215 WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE

The most common treatment-related adverse event was mild self-resolving injection site reaction. There were no reports of pain, no serious adverse events, and no discontinuations.

PHARMACOKINETIC AND PHARMACODYNAMIC RESULTS WERE CONSISTENT WITH THE POTENTIAL FOR CLINICAL BENEFIT UP TO THREE MONTHS

Long estimated half- life and sustained plasma kallikrein inhibition support the potential for dosing once every three months or less frequently.

Introducing ALPHA-STAR
A Clinical Trial of STAR-0215 for People with HAE

The ALPHA-STAR (**A**stria **L**ong-Acting **P**rophylaxis for **H**ereditary **A**ngioedema: **STAR**-0215) trial is a Phase 1b/2 proof-of-concept trial evaluating single and multiple doses of STAR-0215 in people living with HAE types I and II. We expect to initiate the trial in the first quarter of 2023, with initial results in mid-2024. The trial will evaluate safety, tolerability, HAE attack rate, pharmacokinetics, pharmacodynamics, as well as quality of life in people with HAE after single or multiple doses of STAR-0215.

We will continue to share more information about ALPHA-STAR through our newsletter and social media.

Stay in touch!

Sign up to join our community and receive our newsletters in your inbox:
https://astriatx.com/for-patients/patient-newsletters/

For advocacy questions: **advocacy@astriatx.com**
Follow us on social media: **@AstriaTx**

astria THERAPEUTICS

The information provided here is for those affected by HAE and caregivers. STAR-0215 is in preclinical development and not approved in any territory.

1. Preliminary data includes safety through 84 days for all three dose levels, and pharmacokinetics and pharmacodynamics through 84 days for the 100 mg and 300 mg cohorts, and through 56 days for the 600 mg cohort.